CTLA4 and neoplasm: Compared to monotherapy with immune therapy drugs, the mRNA‐4157 vaccine combined with ICI reduced the risk of death or recurrence by 44% in recipients.[32] To determine whether the combination of FAST and ICI could yield a higher anti‐tumor effect, we treated tumor‐bearing mice with FA in combination with PD‐L1 or cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) inhibitors, and found that combination with ICI (α‐PD‐L1 or α‐CTLA‐4) did not significantly enhance the inhibitory effect of FA on distant tumors (Figure S2A–C, Supporting Information).